Galapagos NV
F:GXEA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Galapagos NV
F:GXEA
|
BE |
|
V
|
Vale SA
F:CVLB
|
BR |
|
D
|
Devon Energy Corp
SWB:DY6
|
US |
|
Maha Energy AB
F:7M7
|
SE |
|
Tiger Brands Ltd
F:UG5A
|
ZA |
|
Lonza Group AG
F:LO3
|
CH |
|
Swedbank AB
F:FRYA
|
SE |
|
clearvise AG
F:ABO
|
DE |
|
Kiler Gayrimenkul Yatirim Ortakligi AS
IST:KLGYO.E
|
TR |
|
Unbound Group PLC
F:0UP
|
UK |
|
C
|
Coca-Cola Europacific Partners PLC
F:CK0
|
UK |
|
Lenzing AG
F:LEN
|
AT |
|
Eoptolink Technology Inc Ltd
SZSE:300502
|
CN |
|
S
|
Sandvik AB
DUS:SVKB
|
SE |
|
K
|
Kirin Holdings Co Ltd
DUS:KIR
|
JP |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
S
|
Syros Pharmaceuticals Inc
F:0S9
|
US |
|
K
|
Klevo Rewards Ltd
ASX:KLV
|
AU |
|
M
|
Myriad Genetics Inc
XMUN:MYD
|
US |
Bankruptcy Probability
Galapagos NV's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Galapagos NV Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BE |
|
Galapagos NV
AEX:GLPG
|
1.6B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
368B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
174.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
75B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
60B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Galapagos NV's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Galapagos NV has total debt of 5.2m EUR. This includes both short-term (0 EUR) and long-term (5.2m EUR) debt.
You can find a full breakdown on its Balance Sheet.
